AI-guided solutions to
improve health outcomes for
mothers and their babies

Oli: Working to address unmet needs in women’s health

Oli has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

Oli PPH is the only product to ever identify individuals who are at higher risk of developing postpartum hemorrhage well before they give birth.

Oli PPH is aiming to save lives and reduce the occurrence of irreversibly debilitating outcomes such as emergency hysterectomy, associated with the leading cause of preventable maternal death.
During pregnancy and labour, women today are monitored with technologies similar to what was used on their grandmothers.
2.4x more mothers are dying in the USA today compared to 30 years ago, and globally 2.6M  babies die each year from stillbirth, with little improvement in decades
Oli aims to provide an opportunity to enable what no other device can today - dramatically reduce the unacceptably high rate of preventable complications and deaths during pregnancy and labour
Image
Founded after a traumatic
birth experience.
Determined to prove to the world
we can do better.

Latest News

In our completed 500-patient Pilot study, Oli has shown significant promise in being able to provide early-warning for post-partum hemorrhage - the leading cause of preventable maternal death,...

Baymatob has successfully completed a competitive selection process to join this year’s cohort of the ANDHealth+ commercialisation acceleration program, funded by the Australian Government’s Medical...

Sydney medical device company Baymatob has completed a placement of $4.215 million, with proceeds used to continue in-human clinical trials for its AI-guided labour monitoring device, Oli....